Treatment of HIV infection in combination with other antiretroviral drugs used to treat HIV-1 infection drugs); to prevent mother-to-child transmission of HIV-1, in pregnant women who do not receive antiretroviral therapy during childbirth. Viramune® is indicated and can be used in the mother as a single dose taken orally during childbirth, and in the child, also as a single dose administered orally after birth. In order to minimize the risk of transmission of HIV-1 to the infant, it is recommended that combination therapy be administered to the mother before delivery, whenever possible. Indication: Human immunodeficiency virus [HIV] disease, unspecified. Human immunodeficiency virus [HIV] disease that complicates pregnancy, childbirth and the puerperium.